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Case Report 
Introduction 
      The most common pathology of esopha-
geal cancer is carcinoma including ade-
nocarcinoma and squamous cell carcino-
ma but other histologies may be seen 
(e.g. sarcoma, melanoma and lympho-
ma).synovial sarcomas are a rare entity 
of malignant mesenchymal tumors aris-
ing in periarticular region of the extremi-
ties. Less frequently, they have occurred 
in other sites such as head & neck and 
digestive tract. We describe a primary SS 
of the esophagus in a 28-year-old man. 
Case Report 
An otherwise healthy 28-year-old man pre-
sented with dysphagia to solid foods   and 
epigastric discomfort for about 4 months. 
He had anorexia and weight loss (20 kg) 
from 3 month before admission. There was 
no abnormal finding on Physical examina-
tion. 
 He had no significant medical or family his-
tory. 
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The patient underwent esophagoscopy that 
revealed a large mass that was 19 cm from 
the incisors.   
Biopsy was taken. Biopsy was suggestive 
of low grade spindle cell sarcoma. 
EUS showed giant submucosal lesion from 
muscularis mucosa,18 – 30 cm from  
incisors without any regional lymph nodes. 
Spiral CT scan of the Neck & Thorax 
revealed a large intraluminal tumoral mass 
in the esophagus. 
Multiple lymphadenopathies were detected 
on both sides of the neck. 
Abdominopelvis CT scan was normal. 
 
The patient underwent a transhiatal total 
esophagectomy with gastric pull-up 
through the posterior mediastinum and 
cervical esophagogastric anastomosis. 
The patient thereafter recieved 
chemotherapy (Ifosfamide, Etoposide, 
Mesna  every 3 week for 6 courses). 
Contrary to our recommendation , he 
underwent radiation therapy to the 
mediastinum (54 Gy in 30 fr) in another 
institute. He remained disease-free for 4 
months after radiation therapy. He died 
soon afterwards due to diffuse lung 
metastasis. This case survived about 18 
months.  
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Pathologic findings 
 
Macroscopic examination: a submucosal  
mass of  upper esophagus consists of  
pieces soft ,gray-white tissue totally 
measuring  10*10*5cm . 
Microscopic examination: sections show 
biphasic neoplasm infiltrating squamous-
lined mucosa. Spindle cell component is 
densely cellular with finely dispersed 
chromatin, scant cytoplasm & notable 
mitotic activity. The glandular elements are 
positive for AE1/3 & CK 19.S100,MIC 
2,Ckit,CD34,Desmin,Actin,SMA are 
negative.Bcl2 is positive in some of cells 
of both components. Ki67 stained about 
15% of neoplastic cells. These findings 
confirmed the diagnosis of synovial 
sarcoma of the esophagus. 
Esophageal surgical margins are free of 
tumor. 
Subcarinal lymph node biopsy is negative 
for malignancy. 
Discussion 
Synovial sarcoma (SS) is an uncommon 
malignant mesenchymal tumor of soft 
tissue, involving mainly the periarticular 
region of the extremities such as tendons 
and bursal structures of large joints but 
rarely in the synovium. 
Sometimes their origin is in the head and 
neck and often as parapharyngeal or 
retropharyngeal masses (1). 
Also it has been reported in other sites 
such as abdominal wall and 
retroperitoneum(2,3). 
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Synovial sarcomas of the digestive tract 
are rare neoplasms, particularly in the 
esophagus and account for 0 .l% to 1.5% 
of all esophageal tumors (4). 
Combined histological type sarcomas are 
more frequently seen than pure sarcomas 
and the most common type of the pure 
mesenchymal tumors of the esophagus is 
Leiomyosarcoma. 
The median age at presentation is 58 years 
[range from 26–76 years] [5], and male to 
female ratio is 2 to 1. 
In the esophagus the most common tumor 
site is the cervical to upper third of the 
thoracic esophagus. (22) 
Their pathology may be biphasic, 
monophasic, or poorly differentiated.  
Characteristic histologic findings of 
synovial sarcoma is often a biphasic 
pattern accompanied by an epithelial 
component that  forms clefts and gland-
like spaces, and spindle cell region, 
therefore , diagnosis is made based on the 
presence of the biphasic pattern. In 70 to 
90% of synovial sarcoma, t(X;18) 
translocation is a sensitive marker in 
establishing the diagnosis of synovial 
sarcomas [12]. Other spindle-cell sarcomas 
such as sarcomatoid carcinomas 
(carcinosarcoma), fibrosarcomas, and 
solitary fibrous tumors are among the 
differential diagnoses of biphasic synovial 
sarcomas of the esophagus. 
On immunohistochemistry, 
neuroectodermal antigens such as CD99, 
CD56 and CD57 are often expressed. [21] 
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Also, tumor cells show positive staining 
for the epithelial  elements (eg. cytokeratin 
(AE-1/3) and EMA).  
However, their specificity and sensitivity 
of all of these markers are limited for 
diagnosing synovial sarcoma. It seems 
TLE-1 is the best marker because 
expression being associated with a 
sensitivity and specificity of 75 and 96 %, 
respectively [22]. 
Clinical Features: 
Tumoral mass can cause compression or 
infiltrate the adjacent structures; therefore 
progressive dysphagia is the most common 
complaint. Weight loss, chest discomfort, 
burning retrosternal pain, nausea, and 
vomiting are other symptoms present in 
patients. 
Diagnosis: 
   These tumors are often presented with 
polypoid and exophytic masses on      
Endoscopy [9] and rarely as ulcerating 
tumours [10]. 
Tumoral mass may enhance on CT/MRI 
imaging as intramural mass [11]. 
Treatment: 
 The mainstay of treatment is surgery 
provided that it is feasible [13]. The best 
choice is esophagectomy/
esophagogastrectomy. Therefore for  
resectable tumors, surgery would be the 
first step of treatment while The functional 
outcome is acceptable. 
 In the adjuvant setting, radiotherapy and 
chemotherapy have a controversial role 
[13]. Resection with adequate margins is a 
goal of surgery. So in cases of uncertain 
margins, postoperative radiotherapy would 
be considered. 
 Stenting as a Palliative procedure can 
relieve dysphagia and improve quality of 
life [14].  
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Occasionally, neoadjuvant therapy is also 
considered based on functional outcomes 
and other factors.  
For unresectable lesions, treatment options 
include radiation therapy, chemotherapy, or 
chemoradiotherapy. 
It seems synovial sarcoma is relatively 
chemosensitive according to existing data 
[24], and chemotherapy has improved 
survival in primary synovial sarcoma of 
the extremities [23]. 
The primary chemo therapy regimen 
consists of doxorubicin, ifosfamide, and 
dacarbazine, either alone or in 
combination.  
Today, a number of targeted therapies have 
been considered for adding to 
chemotherapy regimen and they have had 
promising results. For example Pazopanib 
significantly prolonged median progression
-free survival and tended to improve 
overall survival, although this latter trend 
was not significant [25]. 
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The Present Case in the Context of the 
Literature: 
Amr et al. reported a polypoid synovial 
sarcoma arising in the upper third of the 
esophagus in a 25-year-old man and did a 
total esophagectomy followed by 
radiotherapy. This approach  was effective 
[15].  
Bloch et al. reported a case that was treated 
with a local resection and postoperative 
radiation therapy and there was no 
evidence of disease after 36 months [16]. 
Yokoyama et al. did a clinicopathologic 
study of 18 cases and  concluded that 
complete surgical resection of tumors less 
than 5 cm in maximum diameter may be 
curative and that adjuvant chemotherapy 
may not be necessary for such patients, 
because the value of chemotherapy 
for synovial sarcoma is still controversial.
[17].  
On the other hand, Pappo et al. concluded 
that adjuvant chemotherapy is meritted in 
children with resected synovial sarcoma
(clinical group I or II) who present with 
unfavorable clinicopathologic features 
such as large, invasive, or grade 3 
lesions. [18] 
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Holtz et al. reported A 16-year-old boy 
with Synovial Sarcomas of the 
Tongue Base. His tumor was 
resected and Four weeks after 
surgery, a course of radiation 
totaling 6,700 rad to the tumor bed 
was given over eight weeks. The 
patient died 37 months after the 
initial surgery and 40 months after 
the initial symptom with clinical and 
roentgenographic evidence of 
metastases to lungs, liver, bone, 
retroperitoneum, and mediastinum 
despite receiving multi 
chemotherapy agents. Holtz believes 
that the size of the primary tumor is 
the most critical determinant of the 
outcome.[19]. 
S Habo et.al  chose a local excision and 
postoperative radiation and 
chemotherapy(selected minimally 
invasive surgical management thus 
avoiding a total esophagectomy) ; 
patient has shown no evidence of  
recurrence or metastasis 20 months 
postoperatively. They believe that 
Postoperative radiation and chemotherapy 
decreases the rate of local 
recurrence and metastasis [20]. 
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It has not definitely shown that these 
systemic therapies for synovial sarcoma of 
the esophagus are effective. Unfortunately 
The 2-year survival of esophageal synovial 
sarcoma is not very good according to the 
previous studies. 
Genetic features and its role in 
determination of prognosis are under 
consideration. Definitely, these finding are 
contributory factors for selecting the best 
treatment approach for synovial sarcoma of 
the esophagus  
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